Literature DB >> 12057145

Pancreatic cancer.

S J Cohen1, W H Pinover, J C Watson, N J Meropol.   

Abstract

Optimal therapy for pancreatic adenocarcinoma requires surgical removal with tumor-free margins. Superior outcomes have been reported for high-volume centers incorporating a multidisciplinary approach. Postoperative ("adjuvant") chemotherapy and radiation should be considered in patients with successfully resected primary tumors. Combined modality treatment with chemotherapy and radiation should be considered for locally advanced, unresectable tumors. Gemcitabine can provide symptom relief and a modest improvement in survival for patients with metastatic disease. Strict attention to relief of symptoms such as pain, depression, anorexia/cachexia, and jaundice is essential in all patients with pancreatic cancer. All patients with pancreatic cancer should be encouraged to enter clinical trials of new therapies, given that long-term survival for all stages remains poor.

Entities:  

Mesh:

Year:  2000        PMID: 12057145     DOI: 10.1007/s11864-000-0065-2

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  43 in total

Review 1.  Cancer pain relief and palliative care. Report of a WHO Expert Committee.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  1990

2.  Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer.

Authors:  J L Cameron; D W Crist; J V Sitzmann; R H Hruban; J K Boitnott; A J Seidler; J Coleman
Journal:  Am J Surg       Date:  1991-01       Impact factor: 2.565

Review 3.  Association of preoperative biliary drainage with postoperative outcome following pancreaticoduodenectomy.

Authors:  S P Povoski; M S Karpeh; K C Conlon; L H Blumgart; M F Brennan
Journal:  Ann Surg       Date:  1999-08       Impact factor: 12.969

4.  Endoscopic ultrasound-guided real-time fine-needle aspiration biopsy of the pancreas in cancer patients with pancreatic lesions.

Authors:  D O Faigel; G G Ginsberg; J S Bentz; P K Gupta; D B Smith; M L Kochman
Journal:  J Clin Oncol       Date:  1997-04       Impact factor: 44.544

5.  Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas.

Authors:  M Goggins; M Schutte; J Lu; C A Moskaluk; C L Weinstein; G M Petersen; C J Yeo; C E Jackson; H T Lynch; R H Hruban; S E Kern
Journal:  Cancer Res       Date:  1996-12-01       Impact factor: 12.701

6.  Positive peritoneal cytology predicts unresectability of pancreatic adenocarcinoma.

Authors:  N B Merchant; K C Conlon; P Saigo; E Dougherty; M F Brennan
Journal:  J Am Coll Surg       Date:  1999-04       Impact factor: 6.113

7.  Preoperative chemoradiation for patients with pancreatic cancer: toxicity of endobiliary stents.

Authors:  P W Pisters; W A Hudec; J E Lee; I Raijman; S Lahoti; N A Janjan; T A Rich; C H Crane; R Lenzi; R A Wolff; J L Abbruzzese; D B Evans
Journal:  J Clin Oncol       Date:  2000-02       Impact factor: 44.544

8.  Impact of hospital volume on operative mortality for major cancer surgery.

Authors:  C B Begg; L D Cramer; W J Hoskins; M F Brennan
Journal:  JAMA       Date:  1998-11-25       Impact factor: 56.272

9.  Guidelines for the application of surgery and endoprostheses in the palliation of obstructive jaundice in advanced cancer of the pancreas.

Authors:  R P van den Bosch; G P van der Schelling; J H Klinkenbijl; P G Mulder; M van Blankenstein; J Jeekel
Journal:  Ann Surg       Date:  1994-01       Impact factor: 12.969

10.  Changes in nutritional status associated with unresectable pancreatic cancer.

Authors:  S J Wigmore; C E Plester; R A Richardson; K C Fearon
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

View more
  12 in total

1.  Impact of endoscopic ultrasound-guided fine needle biopsy for diagnosis of pancreatic masses.

Authors:  Julio Iglesias-Garcia; Enrique Dominguez-Munoz; Antonio Lozano-Leon; Ihab Abdulkader; Jose Larino-Noia; Jose Antunez; Jeronimo Forteza
Journal:  World J Gastroenterol       Date:  2007-01-14       Impact factor: 5.742

2.  Secreted protein acidic and rich in cysteine inhibits the growth of human pancreatic cancer cells with G1 arrest induction.

Authors:  Zhengfa Mao; Xiaoyan Ma; Xin Fan; Lei Cui; Ting Zhu; Jianguo Qu; Jianxin Zhang; Xuqing Wang
Journal:  Tumour Biol       Date:  2014-07-16

3.  A dose escalation and pharmacodynamic study of triapine and radiation in patients with locally advanced pancreas cancer.

Authors:  Ludmila Katherine Martin; John Grecula; Guang Jia; Lai Wei; Xiangyu Yang; Gregory A Otterson; Xin Wu; Erica Harper; Cheryl Kefauver; Bing-Sen Zhou; Yun Yen; Mark Bloomston; Michael Knopp; S Percy Ivy; Michael Grever; Tanios Bekaii-Saab
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-07-17       Impact factor: 7.038

4.  Percutaneous transgastric computed tomography-guided biopsy of the pancreas using large needles.

Authors:  Hsiuo-Shan Tseng; Chia-Yuen Chen; Wing-P Chan; Jen-Huey Chiang
Journal:  World J Gastroenterol       Date:  2009-12-21       Impact factor: 5.742

5.  Parenteral nutrition support for patients with pancreatic cancer. Results of a phase II study.

Authors:  Uwe Pelzer; Dirk Arnold; Mehmet Gövercin; Jens Stieler; Bernd Doerken; Hanno Riess; Helmut Oettle
Journal:  BMC Cancer       Date:  2010-03-09       Impact factor: 4.430

6.  Feasibility and yield of a novel 22-gauge histology EUS needle in patients with pancreatic masses: a multicenter prospective cohort study.

Authors:  Alberto Larghi; Julio Iglesias-Garcia; Jan-Werner Poley; Geneviève Monges; Maria Chiara Petrone; Guido Rindi; Ihab Abdulkader; Paolo Giorgio Arcidiacono; Guido Costamagna; Katharina Biermann; Erwan Bories; Claudio Doglioni; J Enrique Dominguez-Muñoz; Cesare Hassan; Marco Bruno; Marc Giovannini
Journal:  Surg Endosc       Date:  2013-05-04       Impact factor: 4.584

Review 7.  Drug development in pancreatic cancer: finally, biology begets therapy.

Authors:  Steven J Cohen; Neal J Meropol
Journal:  Int J Gastrointest Cancer       Date:  2002

8.  L-Carnitine-supplementation in advanced pancreatic cancer (CARPAN)--a randomized multicentre trial.

Authors:  Matthias Kraft; Kathleen Kraft; Simone Gärtner; Julia Mayerle; Peter Simon; Eckhard Weber; Kerstin Schütte; Jens Stieler; Heide Koula-Jenik; Peter Holzhauer; Uwe Gröber; Georg Engel; Cornelia Müller; You-Shan Feng; Ali Aghdassi; Claudia Nitsche; Peter Malfertheiner; Maciej Patrzyk; Thomas Kohlmann; Markus M Lerch
Journal:  Nutr J       Date:  2012-07-23       Impact factor: 3.271

9.  A novel biweekly pancreatic cancer treatment schedule with gemcitabine, 5-fluorouracil and folinic acid.

Authors:  P Correale; S Messinese; S Marsili; F Ceciarini; D Pozzessere; R Petrioli; M Sabatino; D Cerretani; M Pellegrini; T Di Palma; A Neri; A Calvanese; E Pinto; G Giorgi; G Francini
Journal:  Br J Cancer       Date:  2003-07-21       Impact factor: 7.640

10.  An open label randomized multicentre phase IIIb trial comparing parenteral substitution versus best supportive nutritional care in subjects with pancreatic adenocarcinoma receiving 5-FU plus oxaliplatin as 2nd or higher line chemotherapy regarding clinical benefit - PANUSCO.

Authors:  Angela Märten; Moritz N Wente; Jennifer Ose; Markus W Büchler; Ingeborg Rötzer; Christiane Decker-Baumann; Irini Karapanagiotou-Schenkel; Sabine Harig; Jan Schmidt; Dirk Jäger
Journal:  BMC Cancer       Date:  2009-11-27       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.